Paradigm Biopharmaceuticals Limited
ASX:PAR.AX
0.235 (AUD) • At close September 19, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) AUD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0.066 | 0.047 | 0.079 | 0.021 | 0 | 2.984 | 2.683 | 1.823 | 1.291 | 0 | 0 |
| Cost of Revenue
| 0.156 | 0.172 | 0.337 | 0.309 | 0.213 | 0.008 | 0.015 | 0.017 | 0.003 | 0 | 0 |
| Gross Profit
| -0.09 | -0.126 | -0.258 | -0.289 | -0.213 | 2.976 | 2.667 | 1.807 | 1.288 | 0 | 0 |
| Gross Profit Ratio
| -1.367 | -2.689 | -3.254 | -14.046 | 0 | 0.997 | 0.994 | 0.991 | 0.998 | 0 | 0 |
| Reseach & Development Expenses
| 58.334 | 52.679 | 39.012 | 33.517 | 12.794 | 7.897 | 6.595 | 4.233 | 2.868 | 0.158 | 0 |
| General & Administrative Expenses
| 0 | 6.565 | 7.934 | 8.748 | 4.167 | 2.319 | 2.332 | 1.891 | 1.451 | 0.22 | 0.231 |
| Selling & Marketing Expenses
| 0 | 0.823 | 0.919 | 0.837 | 1.014 | 2.363 | 0.99 | 0.591 | 0.675 | 1.195 | 0 |
| SG&A
| 6.069 | 6.411 | 7.741 | 8.538 | 3.954 | 4.039 | 2.317 | 1.875 | 1.448 | 1.415 | 0.231 |
| Other Expenses
| 0 | 6.742 | 8.657 | 8.712 | 3.698 | 1.255 | 2.683 | 1.823 | 1.291 | 0 | 0 |
| Operating Expenses
| 64.403 | 59.09 | 46.753 | 42.055 | 16.747 | 11.936 | 8.911 | 6.108 | 4.316 | 1.573 | 0.231 |
| Operating Income
| -64.493 | -59.216 | -47.011 | -42.344 | -16.96 | -11.944 | -8.927 | -6.124 | -4.319 | -1.573 | -0.231 |
| Operating Income Ratio
| -980.133 | -1,266.377 | -593.39 | -2,060.52 | 0 | -4.003 | -3.328 | -3.359 | -3.346 | 0 | 0 |
| Total Other Income Expenses Net
| -0.208 | 0.264 | -0.001 | -0.302 | 1.013 | -6.667 | 0.054 | 0.026 | 0.104 | 0.007 | 0 |
| Income Before Tax
| -64.7 | -58.952 | -47.012 | -42.646 | -15.947 | -18.611 | -8.873 | -6.099 | -4.215 | -1.565 | -0.231 |
| Income Before Tax Ratio
| -983.287 | -1,260.74 | -593.408 | -2,075.226 | 0 | -6.237 | -3.308 | -3.345 | -3.266 | 0 | 0 |
| Income Tax Expense
| -6.047 | -7.042 | -7.763 | -8.349 | -3.648 | -2.984 | -2.683 | -1.823 | -1.291 | 0.007 | 0 |
| Net Income
| -58.653 | -51.91 | -39.25 | -34.297 | -12.299 | -15.628 | -6.19 | -4.275 | -2.924 | -1.565 | -0.231 |
| Net Income Ratio
| -891.386 | -1,110.137 | -495.425 | -1,668.963 | 0 | -5.237 | -2.308 | -2.345 | -2.266 | 0 | 0 |
| EPS
| -0.2 | -0.18 | -0.16 | -0.16 | -0.059 | -0.11 | -0.052 | -0.042 | -0.034 | -0.047 | 0 |
| EPS Diluted
| -0.2 | -0.18 | -0.16 | -0.16 | -0.059 | -0.11 | -0.052 | -0.042 | -0.034 | -0.047 | 0 |
| EBITDA
| -64.346 | -59.062 | -46.817 | -42.134 | -16.747 | -11.936 | -8.911 | -6.108 | -4.316 | 0.007 | 0 |
| EBITDA Ratio
| -977.903 | -1,263.091 | -590.95 | -2,050.298 | 0 | -4 | -3.322 | -3.35 | -3.344 | 0 | 0 |